

Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding

Redeye comments on Amniotics' Q4 report. The company will need funding before it can start an investigator-sponsored clinical trial in lung transplantation with PulmoStem, its lead stem-cell candidate. However, the company is in a problematic financial situation.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Amniotics Q4 2023 - Investigator-sponsored trial in lung transplantation needs funding